INMB
INMB
NASDAQ · Biotechnology

Inmune Bio Inc

$1.63
+0.01 (+0.62%)
As of Jun 30, 10:42 PM ET ·
Financial Highlights (FY 2026)
Revenue
54.1K
Net Income
-50,192,005
Gross Margin
Profit Margin
-91,866.0%
Rev Growth
-48.7%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 61.9% 61.9%
Operating Margin -94,766.0% -85,290.0% 16.6% 15.4%
Profit Margin -91,866.0% -87,272.7% 15.9% 12.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 54.1K 105.4K 11.20M 11.67M
Gross Profit 6.93M 7.23M
Operating Income -51,274,091 -89,919,489 1.85M 1.79M
Net Income -50,192,005 -88,021,832 1.78M 1.44M
Gross Margin 61.9% 61.9%
Operating Margin -94,766.0% -85,290.0% 16.6% 15.4%
Profit Margin -91,866.0% -87,272.7% 15.9% 12.3%
Rev Growth -48.7% -48.7% +3.1% +2.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 11.90M 13.58M
Total Equity 32.54M 29.49M
D/E Ratio 0.37 0.46
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -51,685,348 -95,676,306 2.32M 2.58M
Free Cash Flow 977.1K 708.5K